Position in EXEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$874,586
+$476,825 QoQ
Shares Held
16,074
+73.3% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#347
of 739 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HANTZ FINANCIAL SERVICES, INC. holds $21,275,017 across 57 Biotechnology names. EXEL ranks #6 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
15,883 | $4,781,259 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
58,496 | $4,578,481 | |
| 3 | ARGX |
Argenx SE
|
2,816 | $2,612,600 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
34,865 | $1,233,872 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
3,961 | $954,482 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
16,074 | $874,586 | |
| 7 | CYTK |
Cytokinetics Inc
|
10,063 | $857,266 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
11,424 | $653,681 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $874,586 | 16,074 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $397,761 | 9,274 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $308,212 | 7,032 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $108,949 | 2,638 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $49,986 | 1,134 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $4,024 | 109 | Shares | Sole | 2025-05-12 | |
| No filing history on record for this holder in this stock. | ||||||